Efficacy and Safety of Antimalarial as Repurposing Drug for COVID-19 Following Retraction of Chloroquine and Hydroxychloroquine
Clinical Pharmacology Advances and Applications,
Год журнала:
2025,
Номер
Volume 17, С. 1 - 11
Опубликована: Янв. 1, 2025
Various
repurposing
drugs
have
been
tested
for
their
efficacy
on
coronavirus
disease
2019
(COVID-19),
including
antimalarial
drugs.
During
the
pandemic,
Chloroquine
(CQ)
and
Hydroxychloroquine
(HCQ)
demonstrated
good
potential
against
COVID-19,
but
further
studies
showed
both
had
side
effects
that
were
more
dangerous
than
efficacy.
This
made
World
Health
Organization
(WHO)
ban
usage
COVID-19
patients.
In
this
context,
there
is
a
need
to
explore
other
as
therapies
COVID-19.
study
provides
descriptive
synthesis
of
clinical
trials
evaluating
treatment
conducted
after
withdrawal
CQ
HCQ.
The
method
was
literature
using
keywords
"antimalarial",
"COVID-19",
"SARS-CoV-2",
"clinical
trial",
"randomized
controlled
trial"
MEDLINE,
Scopus,
Cochrane
databases.
Inclusion
criteria
published
with
randomized
(RCTs)
safety
single
in
English
excluding
combination
therapies.
results
3
drugs,
namely
Quinine
Sulfate
(QS),
Atovaquone
(AQ),
Artemisinin-Piperaquine
(AP),
gone
through
trial
assess
Out
only
AP
significant
primary
outcome,
which
time
required
reach
undetectable
levels
SARS-CoV-2.
Furthermore,
intervention
group
took
10.6
days,
control
19.3
days
(p=0.001).
Based
review,
therapy
fight
Язык: Английский
Pharmacodynamic Modeling of Warfarin Dosing Algorithm for Cardiovascular Patients in Indonesia: A Tailored Method to Anticoagulation Therapy
Drug Design Development and Therapy,
Год журнала:
2025,
Номер
Volume 19, С. 671 - 681
Опубликована: Янв. 1, 2025
Warfarin
is
an
anticoagulant
drug
widely
used
for
treating
thromboembolism-related
conditions.
The
main
challenge
with
this
the
high
variability
in
patients
response,
which
influenced
by
both
clinical,
non-clinical,
and
genetic
factors,
such
as
VKORC1,
CYP2C9,
CYP4F2.
Therefore,
research
aimed
to
evaluate
impact
of
clinical
factors
on
warfarin
dose
adjustment
develop
a
dosing
algorithm
cardiovascular
disease.
A
total
77
subjects
were
selected
using
consecutive
sampling
based
inclusion
criteria
cardiac
outpatients
≥3
months
PT-INR
data,
complete
medical
records,
willingness
participate.
Exclusion
included
vitamin
K
use
inability
follow
up.
Patients
demographic
data
characteristics
collected
from
records.
Blood
samples
obtained
testing
CYP4F2
rs2108622
(sequencing).
Statistical
analyses
bivariate
multivariate
(logistic
regression)
significance
level
set
at
<0.05.
analysis
Kruskal-Wallis
test
showed
that
CC,
CT,
TT
genotypes
significantly
associated
(p
=
0.02).
Furthermore,
Mann-Whitney
results
gender
did
not
have
significant
relationship
0.16).
Spearman
Rank
correlation
age
0.02)
BMI
0.03)
had
relationships
<
0.05).
However,
0.89)
no
effect,
while
0.01),
genotype
0.01)
determination.
In
conclusion,
combined
contribution
(8.76%),
(7.95%),
(8.29%)
was
25%.
linear
regression
model
predicting
determined
be
y
12.736-0.16*age
+
0.55*BMI
3.55*genotype,
where
1
2
3
TT.
Язык: Английский
The Efficacy of Oral/Intravenous Corticosteroid Use in COVID-19 Patients: A Systematic Review
Journal of Experimental Pharmacology,
Год журнала:
2024,
Номер
Volume 16, С. 321 - 337
Опубликована: Окт. 1, 2024
The
COVID-19
pandemic
is
prompting
extensive
investigation
into
potential
treatments,
including
the
use
of
corticosteroids
to
manage
inflammation
and
mitigate
severe
disease
outcomes.
Therefore,
this
systematic
review
aimed
evaluate
efficacy
oral/intravenous
in
management
COVID-19.
A
comprehensive
search
was
conducted
across
major
scientific
databases
such
as
MEDLINE,
Scopus,
Cochrane
for
relevant
studies
published
from
2019-2024.
inclusion
criteria
included
investigating
patients
>18
years
with
a
randomized
placebo-controlled
trial
method.
Non-placebo-controlled
studies,
using
combined
treatments
other
drugs,
well
protocol
articles,
conference
proceedings,
non-English
were
excluded.
narrative
synthesis
approach
adopted
given
significant
methodological
diversity.
results
showed
that
total
12
met
covering
three
dexamethasone
(three),
hydrocortisone
(two),
methylprednisolone
(seven).
outcome
parameters
used
each
study
different.
Among
five
insignificant
(two)
while
others
reported
results.
This
suggested
might
confer
clinical
benefits
COVID-19,
particularly
reducing
mortality
However,
further
needed
establish
standardized
protocols
regarding
dosage,
duration,
safety
considerations
optimize
minimize
adverse
effects.
Язык: Английский
Herbal Medicines as Complementary Therapy for Managing Complications in COVID-19 Patients with Diabetes Mellitus
Diabetes Metabolic Syndrome and Obesity,
Год журнала:
2025,
Номер
Volume 18, С. 135 - 146
Опубликована: Янв. 1, 2025
Diabetes
mellitus
(DM)
is
recognized
and
classified
as
a
group
of
conditions
marked
by
persistent
high
blood
glucose
levels.
It
also
an
inflammatory
condition
that
may
influence
concurrent
disease
states,
including
Coronavirus
Disease
2019
(COVID-19).
Currently,
no
effective
drug
has
been
found
to
treat
COVID-19,
especially
in
DM
patients.
Many
herbal
medicines,
such
the
well-known
Andrographis
paniculata,
have
explored
drugs
complementary
therapies
due
their
antidiabetic,
antibacterial,
antiviral,
anti-inflammatory,
immunomodulatory
effects.
This
study
aimed
examine
potential
medicines
therapy
patients
with
COVID-19
complications,
drawing
from
in-vitro
in-vivo
investigations.
analyzed
articles
published
within
last
15
years
using
keywords
"herbal
medicines",
"COVID-19",
"Diabetes
Mellitus",
"antidiabetics",
"antiviral",
"anti-inflammatory".
The
results
showed
several
could
serve
for
complications.
These
include
Ageratum
conyzoides,
Artocarpus
altilis,
Centella
asiatica,
Momordica
charantia,
Persea
gratissima,
Phyllanthus
urinaria,
Physalis
angulata,
Tinospora
cordifolia,
Zingiber
zerumbet.
Herbal
but
these
claims
need
experimental
validation
infection
models
among
affected
Язык: Английский
The Effect of Spinach (Amaranthus hybridus) on the Pharmacokinetic and Pharmacodynamic Profile of Warfarin in New Zealand White Rabbits
Journal of Blood Medicine,
Год журнала:
2025,
Номер
Volume 16, С. 75 - 82
Опубликована: Фев. 1, 2025
Spinach
(Amaranthus
hybridus)
is
a
green
vegetable
containing
380
μg/100
g
of
vitamin
K,
while
warfarin
serves
as
an
antagonist
in
inhibiting
K
epoxide
reductase
subunit
C1
(VKORC).
In
this
context,
the
co-administration
and
spinach
frequently
encountered
among
Indonesian
patients,
potentially
leading
to
drug-food
interactions.
This
study
aimed
investigate
effect
concomitant
administration
on
pharmacokinetic
pharmacodynamic
profile
New
Zealand
White
rabbits.
A
total
24
rabbits
weighing
about
1.5-2
kg
were
used
study.
For
16
days,
these
given
oral
at
dose
0.4
mg/kg
BW
by
10.00
am.
Subsequently,
3
mL
blood
samples
withdrawn
lateral
vein
ear
13th
16th
days.
The
Prothrombin
Time-International
Normalized
Ratio
(PT-INR)
evaluate
profile,
plasma
concentration
S(R)-warfarin
(Cp
(AV)),
half-life
(t½),
area
under
curve
(AUC),
volume
distribution
(Vd),
clearance
(CL)
are
analyzed
determine
effects
warfarin.
Fluconazole
(FZ)
group,
there
was
significant
increase
(AUC)
maximum
(Cmax)
after
treatment,
with
p-value
<
0.05.
Amaranthus
hybridus
1
(AH-1)
2
(AH-2)
groups,
AUC
drug
(AV))
higher
treatment
but
results
statistical
analysis
not
significant.
There
no
or
interaction
between
Additionally,
patients
subjected
therapy
could
consume
recommended
portion
size
below
100
grams
per
day.
Язык: Английский